SEC Form 4 · accession 0001447028-26-000051
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Sawhney
Director
Period of report
Sep 18, 2026
Accepted (ET)
Sep 23, 2026 · 8:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Sep 18, 2026 | M | 52,533 | $3.34 | A | 52,533 | D | |
| Common Shares | Sep 18, 2026 | M | 78,800 | $4.24 | A | 131,333 | D | |
| Common Shares | Sep 18, 2026 | F | 100,508 | $5.07 | D | 30,825 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.34 | Sep 18, 2026 | M | 52,533 | D | — | Aug 4, 2035 | Common Shares | 52,533 | 105,067 | D |
| Stock Option (Right to Buy)F3 | $4.24 | Sep 18, 2026 | M | 78,800 | D | Jun 8, 2026 | Jun 8, 2036 | Common Shares | 78,800 | 0 | D |
Explanation of responses
- F1The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.
- F2The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date.
- F3The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.